<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10674">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02968004</url>
  </required_header>
  <id_info>
    <org_study_id>CP-4-006</org_study_id>
    <nct_id>NCT02968004</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children</brief_title>
  <official_title>A Phase 3, Open-label, Randomized, Multicenter, 12 Months, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin - Therapy in Pre-pubertal Children With Growth Hormone Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Opko Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Opko Biologics</source>
  <brief_summary>
    <textblock>
      This will be an open-label, randomized, multicenter, efficacy and safety study of weekly
      MOD-4023 compared to daily Genotropin therapy in pre-pubertal children with growth hormone
      deficiency.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annual Height Velocity</measure>
    <time_frame>12 months of treatment</time_frame>
    <description>Annual Height Velocity in cm/year measured after 12 months of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Height velocity at 6 months</measure>
    <time_frame>After 6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in height Standard Deviation Score (SDS)</measure>
    <time_frame>After 6 and 12 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone maturation (BM)</measure>
    <time_frame>After 12 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-1 serum levels</measure>
    <time_frame>On day 4(-1) after MOD-4023 dosing across study visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-1 SDS serum levels</measure>
    <time_frame>On day 4(-1) after MOD-4023 dosing across study visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGFBP-3 levels</measure>
    <time_frame>On day 4(-1) after MOD-4023 dosing across study visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGFBP-3 SDS</measure>
    <time_frame>On day 4(-1) after MOD-4023 dosing across study visits</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Pediatric Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>MOD-4023</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotropin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily subcutaneous injection of Somatropin (r-hGH; Genotropin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOD-4023</intervention_name>
    <description>Once weekly subcutaneous injection using pre-filled pen device.</description>
    <arm_group_label>MOD-4023</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin</intervention_name>
    <description>Once daily subcutaneous injection of Genotropin</description>
    <arm_group_label>Genotropin</arm_group_label>
    <other_name>Genotropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pre-pubertal children aged ≥3 years , and not yet 11 years for girls or not yet 12
             years with either isolated GHD, or GH insufficiency as part of multiple pituitary
             hormone deficiency.

          2. Confirmed diagnosis of GHD by two different GH provocation tests defined as a peak
             plasma GH level of ≤10 ng/mL,

          3. Bone age (BA) is not older than chronological age and should be less than 10 for
             girls and less than 11 for boys.

          4. Without prior exposure to any rhGH therapy (naïve patients).

          5. Impaired height velocity defined as:

             o Annualized height velocity (HV) below the 25th percentile for CA (HV &lt; -0.7 SDS)
             and gender according

          6. BMI must be within ±2 SDS of mean BMI for the chronological age and sex.

          7. Baseline IGF-I level of at least 1 SD below the mean IGF-I level standardized for age
             and sex (IGF-I SDS ≤-1)

          8. Normal calculated GFR

          9. Normal 46XX karyotype for girls.

        Exclusion Criteria:

          1. Children with prior history of leukemia, lymphoma, sarcoma or any other forms of
             cancer.

          2. History of radiation therapy or chemotherapy

          3. Malnourished children defined as BMI &lt; -2 SDS for age and sex

          4. Children with psychosocial dwarfism

          5. Children born small for gestational age (SGA - birth weight and/or birth length &lt;-2
             SDS for gestational age)

          6. Presence of anti-hGH antibodies at screening

          7. Chromosomal abnormalities including Turner's syndrome, Laron syndrome, Noonan
             syndrome, Prader-Willi syndrome, Russell-Silver syndrome, SHOX mutations/deletions
             and skeletal dysplasias.

          8. Concomitant administration of other treatments that may have an effect on growth

          9. Major medical conditions and/or presence of contraindication to r-hGH treatment.

         10. Closed epiphyses

         11. Known or suspected HIV-positive patient, or patient with advanced diseases such as
             AIDS or tuberculosis.

         12. Drug, substance, or alcohol abuse.

         13. Known hypersensitivity to the components of study medication.

         14. Other causes of short stature such as celiac disease, uncontrolled primary
             hypothyroidism and rickets.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gili Hart, PhD</last_name>
    <phone>972-8-9300051</phone>
    <email>ghart@opko.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Paul Saenger</name>
      <address>
        <city>Minneola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul saenger, MD, PhD</last_name>
      <email>phsaenger@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>February 20, 2017</lastchanged_date>
  <firstreceived_date>November 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
